CMS (00867) signed a distribution agreement with Novartis for ophthalmic drugs Novartis and Beovu.

CMS (00867) announced that on October 27, 2025, the group signed a distribution agreement with Novartis Pharma Services AG (Novartis) for the monoclonal antibodies injections of Leuzurizumab (trade name: Novartis) and Buxurizumab (trade name: Beiyoushi) . According to the agreement, the group obtained the exclusive import, distribution, sales, and promotional rights for the products in mainland China, while Novartis will continue to be responsible for production and supply of the products. The cooperation period is five years from the effective date of the agreement. Novartis is a globally renowned pharmaceutical company headquartered in Basel, Switzerland. Novartis focuses on four core therapeutic areas (cardiovascular, renal and metabolism, oncology, immunology, neuroscience) and five key technological platforms (chemical therapy, biological therapy, xRNA therapy, radioligand therapy, gene and cell therapy). This collaboration will enhance the overall competitiveness of the group's ophthalmology business company, Kangzhe Visheng, in the field of ophthalmology. Kangzhe Visheng already covers areas such as retinal diseases, eye strain, and glaucoma in ophthalmology. With the addition of Novartis and Beiyoushi, there will be a high level of synergy in customer and expert resources and channel networks with the exclusive drug Sitturin Eye Drops (Digitalis Glycoside Eye Drops) and the exclusive medical device EyeOP1 Glaucoma Treatment Device, thereby enhancing Kangzhe Visheng's academic brand competitiveness in ophthalmology. This will also create a positive push for the continued collaboration and development of urgently needed ophthalmic innovative products, providing more diversified treatment choices for patients with eye diseases. At the same time, Kangzhe Visheng's professional ophthalmology team will integrate market channels and academic resources to improve overall team efficiency, and is expected to have a positive impact on the group's performance.